ArticleNature genetics2020
Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer.
Open access · greenAbstract read
In one paragraph
Article in Nature genetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers.
0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed
9.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 120 citations in OpenAlex.
- Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancer.Cell reports. Medicine · 2025Trial
- Paediatric therapeutic development workshop on desmoplastic small round cell tumours.British journal of cancer · 2026Review
- A prostate cancer-specific super-enhancer at 1q42.3 regulates the CAPN2 and KRT19.The Journal of biological chemistry · 2026Article
- Multi-omics dissection of FOXA1 reveals cancer-type-specific transcriptional networks and functional risk variants.iScience · 2026Article
- FOXA2 in islet biology: Orchestrating pancreatic development and glucose homeostasis.Genes & diseases · 2026Review
- Histone methyltransferase KMT2D promotes castration-resistant prostate cancer progression by reactivating AR through FOXA1.Oncogene · 2026Article
- Identification of targets of clinical FOXA1 mutants involved in EMT and immune suppression in prostate cancer.Communications biology · 2026Article
- Targeting lysine-specific demethylase 1 inhibits melanoma metastasis via the NF2-Hippo-YAP pathway.Cell death & disease · 2026Article
- KIT-dependent acute myeloid leukemias are responsive to LSD1 inhibition.Clinical epigenetics · 2026Article
- GNL3 Orchestrates AR Transcriptional Programs to Drive Castration-Resistant Prostate Cancer and Immune Evasion.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Identification of A p300-SP1-BRD4 Transcriptional Axis as a Key Driver of AR Hyperactivation in Polycystic Ovarian Syndrome.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Serotonin Modulates Lineage Plasticity in Neuroendocrine Prostate Cancer via Epigenetic Reprogramming.Cancer discovery · 2026Article
- KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer.Molecular oncology · 2026Article
- The Histone Methyltransferase KMT2D Is a Critical Mediator of Lineage Plasticity and Therapeutic Response in Castration-Resistant Prostate Cancer.Cancer research · 2026Article
- BRD4-associated chromatin remodelling signature links epigenetic regulation to immune landscape in ovarian cancer.Journal of ovarian research · 2026Article
- Transcriptional and epigenetic reprogramming, lineage plasticity and therapy resistance in prostate cancer.Journal of the National Cancer Center · 2026Review
- Alterations in AR-FOXA1 signaling in prostate cancer progression and therapeutic resistance.Journal of the National Cancer Center · 2026Review
- Systematic investigation of zinc finger MYND-type containing 11-mediated alternative splicing reveals notable events in prostate cancer.Asian journal of urology · 2026Article
- Review
- Review
27 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
22 authors at 4 institutions in 3 countries.
Shuai Gao *Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, USA.ORCID http://orcid.org/0000-0002-7304-8801
Sujun Chen *Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
Dong HanCenter for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, USA.
Zifeng WangCenter for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, USA.
Muqing LiCenter for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, USA.
Wanting HanCenter for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, USA.ORCID http://orcid.org/0000-0002-2173-3647
Anna BesschetnovaCenter for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, USA.
Mingyu LiuCenter for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, USA.
Feng ZhouCenter for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, USA.
David BarrettCenter for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, USA.
My Phu LuongCenter for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, USA.
Jude OwireduCenter for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, USA.
Yi LiangPrincess Margaret Cancer Center/University Health Network, Toronto, Ontario, Canada.
Musaddeque AhmedPrincess Margaret Cancer Center/University Health Network, Toronto, Ontario, Canada.
Jessica PetriccaDepartment of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
Susan PatalanoCenter for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, USA.
Jill A MacoskaCenter for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, USA.
Eva CoreyDepartment of Urology, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-9244-3807
Sen ChenHematology-Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Steven P BalkHematology-Oncology Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA. sbalk@bidmc.harvard.edu.ORCID http://orcid.org/0000-0002-4546-7371
Housheng Hansen HeDepartment of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada. hansenhe@uhnresearch.ca.ORCID http://orcid.org/0000-0003-2898-3363
Changmeng CaiCenter for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA, USA. changmeng.cai@umb.edu.ORCID http://orcid.org/0000-0002-8701-2586
University of Massachusetts Boston · USBeth Israel Deaconess Medical Center · USUniversity Health Network · CAUniversity of Washington · US
Funding
U Mass Boston / DFHCC U54 Partnership (1 of 2)U54CA156732 · NCI · DANA-FARBER CANCER INST · PI WENDY Beth LONDON · 2010 to 2026
$25.6MSteroid Metabolism in Castration-Resistant Prostate CancerP01CA163227 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Steven P. Balk · 2013 to 2026
$25.0MUMass Boston-DF/HCC U54 Partnership (2 of 2)U54CA156734 · NCI · UNIVERSITY OF MASSACHUSETTS BOSTON · PI ADAN COLON-CARMONA, Jill A. Macoska · 2010 to 2026
$24.9MRole of Beta-Catenin in Urinary DysfunctionU54DK104310 · NIDDK · UNIVERSITY OF WISCONSIN-MADISON · PI MACOSKA, JILL A., MARKER, PAUL C · 2014 to 2023
$12.8MInitiative for Maximizing Student Diversity at UMass BostonR25GM076321 · NIGMS · UNIVERSITY OF MASSACHUSETTS BOSTON · PI COLON-CARMONA, ADAN, SKVIRSKY, RACHEL · 2008 to 2022
$4.5MStudy the Mechanism of Retinoblastoma Protein Mediated Androgen Receptor Transcriptional Repression Activity on DNA ReplicationR01CA211350 · NCI · UNIVERSITY OF MASSACHUSETTS BOSTON · PI CAI, CHANGMENG · 2017 to 2021
$1.7MMolecular basis of androgen receptor mediated gene transcriptional repressionR00CA166507 · NCI · UNIVERSITY OF MASSACHUSETTS BOSTON · PI CAI, CHANGMENG · 2015 to 2017
$726kCIHR 142246CIHR 152863CIHR 152864CIHR 159567NCI NIH HHS P01 CA163227NCI NIH HHS R00 CA166507NCI NIH HHS R01 CA211350NCI NIH HHS U54 CA156732NCI NIH HHS U54 CA156734NIDDK NIH HHS U54 DK104310NIGMS NIH HHS R25 GM076321
Abstract
FOXA1 functions as a pioneer transcription factor by facilitating the access to chromatin for steroid hormone receptors, such as androgen receptor and estrogen receptor
Indexed as
Androgen Receptor AntagonistsAnimalsCell Line, TumorChromatinDNA-Binding ProteinsDNA MethylationGene Expression Regulation, NeoplasticGene Knockout TechniquesGonadal Steroid HormonesHepatocyte Nuclear Factor 3-alphaHeterograftsHistone DemethylasesHumansMaleMiceProstateAndrogen Receptor AntagonistsChromatinDNA-Binding ProteinsFOXA1 protein, humanGonadal Steroid HormonesHepatocyte Nuclear Factor 3-alphaHistone DemethylasesKDM1A protein, humanReceptors, Androgen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.